Melanotan II

Melanotan II is a synthetic melanocortin peptide used almost exclusively off-label — the primary draws are skin tanning and pigmentation, followed by libido enhancement, with some users also reporting appetite suppression. The single practitioner-tier source available puts the typical dose at 250 mcg subcutaneously at bedtime, with 100 mcg as the low end, run in 4–6 week cycles. There is no approved indication anywhere — every use is off-label or compounded — and injection-site reactions come up consistently across community reports.

Melanotan II

Research Evidence

Evidence shape

Clinical evidence for Melanotan II is low despite one Phase 3 registration: four trials across nephrotic syndrome, insomnia, and non-segmental vitiligo, with no indication producing results at scale. Nephrotic syndrome draws the most coverage at two trials, both exploratory; the other indications are single-trial entries without posted findings. Outside the trial registry, the research base is preclinical only.

Depthhow much
4 registered trials
2 completed · 1 recruiting / active
Breadthhow many areas
4 indications mapped
3 thin / exploratory · 1 animal-only · 2 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
2 distinct sponsors · 3 linked publications on registered trials
Breadth and depth28 rows captured
Human
direct clinical signal
4
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

1
Nextgenpeps
US
10 mg
$0.44
$0.044/mg
2
High Purity Peptides
HK
100 mg
$50.00
$0.5/mg
3
Sentinel Valor
US
10 mg
$4.99
$0.5/mg
4
Prism Aminos
US
100 mg
$123.75
$1.24/mg
5
Edge Peptides
CN
100 mg
$140.00
$1.4/mg
6
Buy Retatrutide
UK
100 mg
$150.00
$1.5/mg

price offers can be sorted by column

1-6 of 100

Dosing & Protocol

How Melanotan II is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 1
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

1 completed trial identified; trial dosing not reliably extracted from registry data.

2 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
250 µg100 µg – 250 µg
50 µg
125 µg
250 µg
1 mg
2 mg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 100 µg–250 µg daily subQ (1 source).

1 source
Anecdotal
Community-reported real-world use · n = 35
Typical dose
500 µg50 µg – 2.5 mg
typical
50 µg
125 µg
250 µg
1 mg
2 mg
distribution of 24 reported doses · darker = more reports
By reported cadence
Daily500 µg (100 µg–500 µg) · n=3
2×/week200 µg · n=2
Schedule unstated100 µg (50 µg–2.5 mg) · n=13
Frequency
mixed
Timing
unspecified
Route
subQ
Cycle
unspecified

Reported doses span 50 µg–2.5 mg, most commonly 500 µg; schedules vary, most often daily.

15 sources

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Melanotan II, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.